Denali Therapeutics(NASDAQ) DNLI

Denali creates medicines for serious brain and body diseases. It uses technology to help drugs reach the brain. These treatments target rare disorders and conditions like Alzheimer's.

What Denali Is Developing

• Enzyme Transport Vehicle: Biotherapeutic enzymes designed to cross the blood-brain barrier to treat rare genetic diseases that affect the nervous system and body.
• Oligonucleotide Transport Vehicle: Genetic medicines that use the company's delivery platform to modify gene expression in the brain for treating neurodegenerative disorders.
• Antibody Transport Vehicle: Engineered antibodies that target brain pathologies, such as amyloid plaques in Alzheimer's disease, with improved safety and brain distribution.
• Small Molecule Inhibitors: Chemical drugs like BIIB122, which is a LRRK2 inhibitor designed to cross the blood-brain barrier for the treatment of Parkinson's disease.

Scaling Up and Partnering Out

• Submitted a Biologics License Application (BLA)—a request to market a new biologic drug—to the FDA for tividenofusp alfa in May 2025.
• Opened a new clinical biomanufacturing facility in Salt Lake City, Utah, in March 2025 to increase drug supply control.
• Entered a $75 million development funding agreement with a third party in January 2024 to support Parkinson's disease clinical trials.
• Secured alignment with the FDA in August 2025 on a path for accelerated approval of DNL126 to treat Sanfilippo syndrome.
• Advanced the PTV:PGRN program for frontotemporal dementia through a global co-development and co-commercialization partnership with Takeda.

Reaching Into the Brain

Denali uses a proprietary Transport Vehicle technology to bypass the blood-brain barrier. This barrier is a tight layer of cells that usually prevents large medicine molecules from reaching brain tissue.

Recent Financial Results

• Operating Income was -$137.4 million in Q4 2025, down 5.8% year-over-year.
• Net Income reached -$128.5 million in Q4 2025, down 12% from the previous year.
• Free cash flow hit -$100.1 million in Q4 2025, down 12.7% year-over-year.
• Market capitalization was $2.9 billion in Q4 2025, down 16.4% from the prior year.

Bottom Line

Denali has evolved from a research-stage platform into a clinical-stage company preparing for its first potential commercial product launches. Its specialized focus on crossing the blood-brain barrier positions it as a pioneer in the treatment of complex neurological and genetic diseases.